Exblifep (cefepime, enmetazobactam)
Research Synopsis
- * Recent studies demonstrated that enmetazobactam significantly enhances cefepime's effectiveness by inhibiting ESBLs, which have been a major cause of antimicrobial resistance.
- * Laboratory tests indicated that the cefepime-enmetazobactam combination could serve as an alternative to carbapenems for treating complex urinary tract infections and other severe Gram-negative infections.
- * Quality control measures for susceptibility testing of cefepime-enmetazobactam have been established, ensuring accurate guidelines for clinical usage, with validation from the Clinical and Laboratory Standards Institute (CLSI).
- * Pharmacodynamic studies in murine models show that the combination of cefepime and enmetazobactam leads to a significant increase in antimicrobial action, especially against ESBL-producing pathogens.
- * Clinical assessments and retrospective studies suggest that cefepime-enmetazobactam is effective against a variety of clinical isolates, with ongoing clinical trials needed to validate these findings further.
- * Initial pharmacokinetic studies in healthy volunteers indicate that cefepime-enmetazobactam reaches effective concentrations in the lungs, highlighting its potential use for treating nosocomial pneumonia.
- * In comparison to other new antibiotic combinations like cefepime-zidebactam, studies suggest cefepime-enmetazobactam holds promise against resistant Gram-negative bacteria, showing comparable or enhanced efficacy.
- * Research indicates a trend toward favoring novel β-lactam/β-lactamase inhibitor combinations, such as cefepime-enmetazobactam, as frontline treatments in cases of serious ESBL infections, enhancing global health responses to antibiotic resistance.
- * Continuous monitoring of cefepime-enmetazobactam's efficacy and resistance mechanisms is essential as the global landscape of antimicrobial resistance evolves.
Exblifep (cefepime, enmetazobactam)
Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination.
London, UK
2 hours ago
1 Received
- * AAI101 is a new β-lactamase inhibitor designed to improve the effectiveness of existing antibiotics, particularly cefepime, by enhancing its ability to penetrate bacterial cells and restoring its activity against ESBLs.
- * Studies, including tests on mice, suggest that the AAI101 and cefepime combination could be a promising treatment approach for severe infections caused by resistant bacteria, potentially reducing reliance on more powerful antibiotics like carbapenems.
$100 - $150
Hourly Rate
Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.
London, UK
2 hours ago
1 Received
- Enmetazobactam is a new drug that inhibits extended-spectrum β-lactamases and is being tested in combination with cefepime for treating complicated urinary tract infections.
- In lab tests, enmetazobactam significantly lowered the minimum inhibitory concentration (MIC) of cefepime against several clinical isolates, making cefepime much more effective.
- This combination may be a promising alternative to carbapenems for treating serious infections caused by Gram-negative bacteria, especially those producing ESBLs.
$100 - $150
Hourly Rate
Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
London, UK
2 hours ago
1 Received
- * Enmetazobactam is a new β-lactamase inhibitor that works effectively against various ESBLs and is currently in phase 3 trials in combination with cefepime for complicated urinary tract infections.
- * Quality control (QC) measures involving broth microdilution MIC and disk diffusion tests have been established to ensure accurate testing of cefepime-enmetazobactam susceptibility, validated by the Clinical and Laboratory Standards Institute (CLSI) in 2017 and 2019.
$100 - $150
Hourly Rate
Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of enmetazobactam and cefepime in human plasma.
London, UK
2 hours ago
1 Received
- A method using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was created to analyze enmetazobactam and cefepime in human plasma samples.
- *The process involved protein precipitation with acetonitrile and separation through a specific HILIC column using a mobile phase made from ammonium formate in water and acetonitrile.
- *Validation results showed high precision and accuracy, with a lower limit of quantification of 0.05 μg/mL for enmetazobactam and 0.5 μg/mL for cefepime across multiple tests.
$100 - $150
Hourly Rate
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing .
London, UK
2 hours ago
1 Received
- * A study investigated the effectiveness of cefepime combined with the beta lactamase inhibitor enmetazobactam against ESBL-producing bacteria using a mouse model for pneumonia, focusing on how the drugs distribute and act in the lungs.
- * Results showed that while cefepime alone was minimally effective, combining it with enmetazobactam significantly enhanced its antimicrobial action, indicating a promising new treatment strategy for serious infections caused by ESBL-producing organisms.
$100 - $150
Hourly Rate
Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.
London, UK
2 hours ago
1 Received
- Third-generation cephalosporin-resistant pathogens, particularly those with extended-spectrum β-lactamases (ESBLs), are critical threats to treatment and are targeted in developing new antibiotics.
- Enmetazobactam, a new ESBL inhibitor combined with cefepime, has been studied for its effectiveness against serious Gram-negative infections, specifically in complicated urinary tract infections.
- Research indicates that enmetazobactam can restore the efficacy of cefepime against resistant bacterial isolates, and establishes important pharmacokinetic-pharmacodynamic targets to enhance treatment effectiveness.
$100 - $150
Hourly Rate
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
London, UK
2 hours ago
1 Received
- The study evaluates the effectiveness of new combinations of antibiotics (imipenem-relebactam and cefepime-AAI101) against multidrug-resistant Enterobacteriaceae.
- Researchers used agar-based tests on 264 samples to compare these new combinations with existing treatments and test their activity against various β-lactamases.
- Results showed that while the new combinations improved susceptibility to certain resistant bacteria, alternative therapies might be needed for strains not responsive to current options.
$100 - $150
Hourly Rate
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
London, UK
2 hours ago
1 Received
- Cefepime-enmetazobactam is a new antibiotic combination developed to treat serious hospital infections, particularly those caused by multidrug-resistant bacteria.
- A study on 20 healthy volunteers assessed how well this drug penetrates lung tissue, measuring levels in both plasma and epithelial lining fluid (ELF) using sophisticated lab techniques.
- The findings suggest that the drug reaches effective concentrations in the lungs, with a high probability of successfully targeting multidrug-resistant infections, supporting its potential use for treating hospital-acquired pneumonia.
$100 - $150
Hourly Rate
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
London, UK
2 hours ago
1 Received
- The rise of extended-spectrum β-lactamases (ESBLs) in Enterobacteriales poses a significant global health threat, leading to increased reliance on carbapenems for treatment, which in turn contributes to the emergence of carbapenem-resistant infections.
- While piperacillin-tazobactam is not a viable first-line option for severe ESBL infections, it may be useful for less severe cases or as a step-down therapy in certain situations.
- New β-lactam/β-lactamase inhibitor (BL/BLI) combinations show promise as alternative treatments for serious ESBL infections, but further clinical trials are necessary to assess their effectiveness compared to carbapenems.
$100 - $150
Hourly Rate
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
London, UK
2 hours ago
1 Received
- * The rise of extended-spectrum β-lactamases (ESBLs) poses a challenge to cefepime, but research is focused on new combinations with β-lactamase inhibitors (BLIs) to combat this issue, with four new combinations currently in development.
- * Among these combinations, cefepime/zidebactam and cefepime/taniborbactam show activity against resistant bacteria, and ongoing clinical trials are evaluating their effectiveness compared to traditional treatments for complicated urinary tract infections.
$100 - $150
Hourly Rate
Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
London, UK
2 hours ago
1 Received
- This study explored resistance to third-generation cephalosporins (3GCs) in clinical Enterobacterales, focusing on resistance factors like ESBLs and AmpC β-lactamases, and evaluated the effectiveness of various antibiotic combinations including a new option, cefepime/enmetazobactam.
- Out of 7168 clinical isolates tested between 2016 and 2018, 17.5% showed phenotypic resistance to 3GCs, while only 2.1% were resistant to the carbapenem meropenem, with the majority of resistant strains producing ESBLs.
- The study found that while the majority of 3GC-resistant isolates showed moderate
$100 - $150
Hourly Rate
Sigmoid Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.
London, UK
2 hours ago
1 Received
- The rise of carbapenem resistance is linked to the use of carbapenem antibiotics for infections caused by aggressive extended-spectrum β-lactamases (ESBLs).
- Enmetazobactam is a new inhibitor being combined with cefepime to provide an alternative treatment that spares carbapenems for ESBL-producing bacteria.
- Testing showed that a concentration of 8 μg/ml of enmetazobactam can significantly restore cefepime's effectiveness against most cefepime-resistant ESBL-producing Klebsiella pneumoniae isolates.
$100 - $150
Hourly Rate
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
London, UK
2 hours ago
1 Received
- The study focused on the effectiveness of different antibiotics against carbapenem-nonsusceptible Enterobacterales (CNSE) derived from 16 hospitals in Taiwan, analyzing 201 non-duplicate isolates, mainly E. coli and K. pneumoniae.
- Results showed cefiderocol was the most effective, with only a small percentage of isolates being resistant, while ceftazidime/avibactam and cefepime/zidebactam also showed high susceptibility rates.
- Carbapenemase genes were present in a notable portion of K. pneumoniae isolates, indicating significant resistance, but the study highlights the potential of specific antibiotics as treatment options for these resistant strains.
$100 - $150
Hourly Rate
Role of new antibiotics in extended-spectrum β-lactamase-, AmpC- infections.
London, UK
2 hours ago
1 Received
- The review focuses on the significant threat posed by ESBL- and AmpC-producing Enterobacterales and highlights recent efforts to develop new antibiotics to combat these resistant bacteria.!* -
- Several new therapeutic agents, such as ceftazidime-avibactam and ceftolozane-tazobactam, have been approved and show promise as alternatives to traditional carbapenems for treating serious Gram-negative infections.!* -
- While these new agents have unique properties, more clinical research is needed to determine their effectiveness and optimal use compared to existing treatments like carbapenems in patients with severe infections caused by these resistant bacteria.!*
$100 - $150
Hourly Rate
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing .
London, UK
2 hours ago
1 Received
- Carbapenemases like KPC, OXA-48, and metallo-β-lactamases (MBLs) are concerning because they resist traditional beta-lactamase inhibitors, prompting the development of new inhibitors for treating multidrug-resistant bacteria.
- A study involving cefepime combined with new beta-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam analyzed 400 carbapenemase-producing strains, revealing various resistance mechanisms and significant rates of cefepime resistance at 79.5%.
- Cefepime/zidebactam and cefepime/taniborbactam combinations showed strong antibacterial activity, making them promising alternatives to conventional
$100 - $150
Hourly Rate
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.
London, UK
2 hours ago
1 Received
- Bacterial resistance mechanisms, especially in Gram-negative bacteria, are evolving rapidly, prompting the need for new treatment strategies.
- Recent developments in β-lactam/β-lactamase inhibitors (BLs/BLIs) have shown promising results from phase 3 and real-world studies, with cefiderocol highlighted for its unique action.
- An overview of various compounds, including aztreonam/avibactam and meropenem/vaborbactam, is provided by experts, featuring tables that summarize clinical outcomes, mechanisms, and pharmacological properties.
$100 - $150
Hourly Rate
Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing .
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing ".
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Multicenter surveillance of activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against , and complex causing bloodstream infection in Taiwan, 2020.
London, UK
2 hours ago
1 Received
- The study aimed to evaluate the effectiveness of new and existing antibiotics against Gram-negative bacteria in Taiwan.
- Researchers collected samples from various sources and measured the minimum inhibitory concentrations (MICs) of the antibiotics using specific testing methods, while also identifying resistance genes in non-susceptible isolates.
- Results indicated that the cefepime-enmetazobactam combination was highly effective against certain drug-resistant bacteria, highlighting the importance of ongoing monitoring of novel antibiotics in clinical settings.
$100 - $150
Hourly Rate
Management of clinical infections of by new β-lactam/β-lactamase inhibitor combinations.
London, UK
2 hours ago
1 Received
- A study was conducted to evaluate the effectiveness of new combinations of β-lactam antibiotics and β-lactamase inhibitors against 140 clinical isolates from infections, revealing a significant resistance problem in traditional treatments.* -
- The research found that 46.4% of the isolates produced extended spectrum β-lactamase (ESBL), with high resistance rates to classical combinations like amoxicillin/clavulanate (40.7%) and ampicillin/sulbactam (42.9%).* -
- New combinations, particularly ceftazidime/avibactam, showed promising results, making 94.3% of the resistant isolates susceptible, suggesting these novel treatments may restore effectiveness against
$100 - $150
Hourly Rate